Insmed News

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024

BRIDGEWATER, N.J., April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,

PR NewswireApr 25 08:00 ET

Express News | Insmed Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $48

Moomoo 24/7Apr 23 07:10 ET

Insmed Initiated at Buy by Truist Securities

Insmed Initiated at Buy by Truist Securities

Dow JonesApr 23 06:50 ET

Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)

TipRanksApr 23 06:40 ET

Express News | Truist Securities Initiates Coverage On Insmed With Buy Rating, Announces Price Target of $48

Moomoo 24/7Apr 23 06:40 ET

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)

TipRanksApr 16 13:20 ET

Insmed Is Maintained at Overweight by Barclays

Insmed Is Maintained at Overweight by Barclays

Dow JonesApr 11 09:40 ET

Express News | Insmed Inc : Barclays Raises Target Price to $40 From $37

Moomoo 24/7Apr 11 07:11 ET

What Makes Insmed (INSM) a Lucrative Investment?

Yahoo FinanceApr 10 12:40 ET

Express News | Insmed Shares Are Trading Higher After Wells Fargo Maintained an Overweight Rating on the Stock and Maintained Its Price Target of $55

Moomoo 24/7Apr 4 08:25 ET

Insmed Incorporated's (NASDAQ:INSM) Price Is Out Of Tune With Revenues

With a median price-to-sales (or "P/S") ratio of close to 13.8x in the Biotechs industry in the United States, you could be forgiven for feeling indifferent about Insmed Incorporated's (NASDAQ:INSM) P/S ratio of 12.8x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

Simply Wall StApr 3 08:43 ET

Insmed Is Maintained at Overweight by Wells Fargo

Insmed Is Maintained at Overweight by Wells Fargo

Dow JonesApr 1 12:11 ET

Express News | Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target

Moomoo 24/7Apr 1 12:01 ET

Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)

TipRanksApr 1 06:03 ET

Express News | Insmed Incorporated To Present Nine Abstracts From Across Its Respiratory Portfolio At American Thoracic Society 2024 International Conference

Moomoo 24/7Mar 27 16:17 ET

Insmed to Present New Data From Across Its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Insmed Incorporated (Nasdaq: INSM) today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.

PR NewswireMar 27 16:05 ET

Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed's Brensocatib

TipRanksMar 19 02:08 ET

Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)

TipRanksMar 12 08:20 ET

On March 8, Insmed Received Notice Of Exercise By Astrazeneca AB Of Its Second And Final Option Under License Agreement, Dated Oct 4, 2016

- SEC FilingOn March 8, 2024, Insmed Incorporated (the "Company") received notice of the exercise by AstraZeneca AB ("AstraZeneca") of its second and final option under the License Agreement, dated Oc

BenzingaMar 11 09:35 ET

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)

TipRanksMar 7 07:30 ET